HCW Biologics
HCWB
13 hedge funds and large institutions have $424K invested in HCW Biologics in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
44% more funds holding
Funds holding: 9 → 13 (+4)
1.74% more ownership
Funds ownership: 0.96% → 2.7% (+1.7%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
7% less capital invested
Capital invested by funds: $457K → $424K (-$32.8K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$850K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$62.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$56.8K |
| 4 |
JWCA
J.W. Cole Advisors
Tampa,
Florida
|
+$35.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$136K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$1.97K |
| 3 |
Citigroup
New York
|
-$884 |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $291K | +$850K | +50,030 | New |
|
|
DS
2
DRW Securities
Chicago,
Illinois
| $34.2K | -$136K | -8,026 | -58% |
|
|
3
Citadel Advisors
Miami,
Florida
| $21.5K | +$62.8K | +3,693 | New |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $19.5K | +$56.8K | +3,345 | New |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $15K | – | – | – |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| $13.6K | +$8.6K | +506 | +28% |
|
|
JWCA
7
J.W. Cole Advisors
Tampa,
Florida
| $12.1K | +$35.4K | +2,083 | New |
|
|
GSWM
8
Golden State Wealth Management
Santa Ana,
California
| $9.71K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $4.37K | +$8.34K | +491 | +189% |
|
10
UBS Group
Zurich,
Switzerland
| $1.69K | +$4.93K | +290 | New |
|
|
11
Wells Fargo
San Francisco,
California
| $971 | -$1.97K | -116 | -41% |
|
12
Osaic Holdings
Scottsdale,
Arizona
| $25 | – | – | – |
|
13
Bank of America
Charlotte,
North Carolina
| $11 | – | – | – |
|
|
14
Citigroup
New York
| $1 | -$884 | -52 | Closed |
|
|
SS
15
SBI Securities
Tokyo,
Japan
| – | -$4 | – | – |
|
HCWB Hedge Fund Activity: Q4 2025 in Review
13 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in HCW Biologics (HCWB) for Q4 2025, worth a combined $424K — down 7.2% from $457K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new HCWB positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $850K. The largest seller was DRW Securities, cutting an estimated $136K.
- 13 institutional investors held HCW Biologics (HCWB) as of Q4 2025, up from 9 in Q3 2025.
- Funds reported $424K of HCW Biologics stock for Q4 2025, down 7.2% quarter-over-quarter.
- 5 funds opened new HCW Biologics positions in Q4 2025 and 1 closed out, a net change of +4 holders.
- The largest HCW Biologics buyer in Q4 2025 was Armistice Capital, an estimated $850K added.
- The largest HCW Biologics seller in Q4 2025 was DRW Securities, an estimated $136K sold.
Based on aggregated 13F filings for Q4 2025.